Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Link opens in a new tab
Search content at Bar-Ilan University
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Human herpesvirus 8 and lymphoproliferative disorders
Maria Luisa Calabrò
,
Ronit Sarid
The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University
IRCCS Istituto Oncologico Veneto - Padova
Research output
:
Contribution to journal
›
Review article
›
peer-review
29
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Human herpesvirus 8 and lymphoproliferative disorders'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
HHV-8
100%
Lymphoproliferative Disorders
100%
Idiopathic multicentric Castleman Disease (iMCD)
55%
Primary Effusion Lymphoma
44%
Infected Individual
22%
Human Immunodeficiency Virus Type 1 (HIV-1)
22%
Plasmablastic
22%
Diffuse Large B-cell Lymphoma (DLBCL)
22%
B Cells
11%
Developmental Stages
11%
Dysregulated
11%
Overall Survival
11%
Distinctive Features
11%
Pathologic Conditions
11%
Herpesvirus
11%
Neoplastic Disorders
11%
Immunocompromised Patients
11%
Conventional Therapy
11%
Lymphoma Patients
11%
Inflammatory Niche
11%
Immunity System
11%
Immune-competent
11%
Extracavitary
11%
Not Otherwise Specified
11%
Extracavitary Primary Effusion Lymphoma
11%
Germinotropic Lymphoproliferative Disorder
11%
Leukemic Phase
11%
Non-Hodgkin B-cell Lymphoma
11%
Body Cavity
11%
Medicine and Dentistry
Human Herpesvirus 8
100%
Lymphoproliferative Disease
100%
Angiofollicular Lymph Node Hyperplasia
62%
Primary Effusion Lymphoma
62%
Disease
37%
Infection
25%
Human Immunodeficiency Virus
25%
Diffuse Large B-Cell Lymphoma
25%
B Cell
12%
Overall Survival
12%
Herpesviridae
12%
B-Cell Lymphoma
12%
Immunocompromised Patient
12%
Developmental Stage
12%
Immunology and Microbiology
Lymphoproliferative Disorders
100%
Human Herpesvirus 8
100%
Castleman's Disease
62%
B Cell
37%
Human Immunodeficiency Virus 1
25%
Herpesviridae
12%
Overall Survival
12%
Immunocompromised Patient
12%
Developmental Stage
12%